South Korea’s Pharmcadd bags $16M in series B financing, plans 2022 IPO

On April 26, 2021 Pharmcadd Co. Ltd., a developer of an artificial intelligence (AI) and physics-based drug discovery platform, bagged ₩17.3 billion (US$15.5 million) in its series B funding (Press release, PharmCADD, APR 26, 2021, View Source [SID1234644208]). This brings the total funds raised since its establishment to $22 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!